The researchers’ goal was to describe the clinical characteristics and therapeutic options available to pediatric patients with cluster headache.
Rimegepant is an oral calcitonin gene-related peptide receptor antagonist.
No cases of postdural puncture headache (PDPH) were reported in a cohort of patients receiving spinal injections with smaller or larger needles for spinal anesthesia during orthopedic procedures.
Besides acetaminophen, NSAIDs, triptans, ergot alkaloids, and adjunct antiemetics, gepants and ditans are recently approved for migraine patients.
Atorvastatin may have augmentative effects with sodium valproate in the reduction of migraines with aura.
Data analysis revealed that CGRP mAbs were discontinued more frequently than onabotulinumtoxinA (23% vs 3%).
Researchers believed the MIDAS questionnaire would improve communication and aid in the diagnosis of migraines.
The researchers compared anti-CGRP mAbs with other drugs for the prevention of episodic and chronic migraine using a likelihood to help versus harm analysis.
This study’s main goal was to investigate how ONS acts on patients’ protective mechanisms and pain-defending protective reﬂexes.
Atogepant is an investigational orally administered calcitonin gene-related peptide (CGRP) receptor antagonist.